

---

---

**Molecular in vitro diagnostic  
examinations — Specifications for  
pre-examination processes for venous  
whole blood —**

**Part 1:  
Isolated cellular RNA**

*Analyses de diagnostic moléculaire in vitro — Spécifications relatives  
aux processus préanalytiques pour le sang total veineux —*

*Partie 1: ARN cellulaire extrait*

ISO 20186-1:2019

<https://standards.iteh.ai/catalog/standards/iso/5679f06c-d055-401a-b0f6-ed9a5b033a5d/iso-20186-1-2019>



iTeh Standards  
(<https://standards.iteh.ai>)  
Document Preview

[ISO 20186-1:2019](https://standards.iteh.ai/catalog/standards/iso/5679f06c-d055-401a-b0f6-ed9a5b033a5d/iso-20186-1-2019)

<https://standards.iteh.ai/catalog/standards/iso/5679f06c-d055-401a-b0f6-ed9a5b033a5d/iso-20186-1-2019>



**COPYRIGHT PROTECTED DOCUMENT**

© ISO 2019

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office  
CP 401 • Ch. de Blandonnet 8  
CH-1214 Vernier, Geneva  
Phone: +41 22 749 01 11  
Fax: +41 22 749 09 47  
Email: [copyright@iso.org](mailto:copyright@iso.org)  
Website: [www.iso.org](http://www.iso.org)

Published in Switzerland

# Contents

Page

<b>Foreword</b> .....	<b>iv</b>
<b>Introduction</b> .....	<b>v</b>
<b>1 Scope</b> .....	<b>1</b>
<b>2 Normative references</b> .....	<b>1</b>
<b>3 Terms and definitions</b> .....	<b>1</b>
<b>4 General considerations</b> .....	<b>5</b>
<b>5 Outside the laboratory</b> .....	<b>6</b>
5.1 Specimen collection.....	6
5.1.1 Information about the specimen donor/patient.....	6
5.1.2 Selection of the venous whole blood collection tube by the laboratory.....	6
5.1.3 Venous whole blood specimen collection from the donor/patient and stabilization procedures.....	6
5.1.4 Information about the specimen and storage requirements at the blood collection facility.....	7
5.2 Transport requirements.....	8
<b>6 Inside the laboratory</b> .....	<b>8</b>
6.1 Specimen reception.....	8
6.2 Storage requirements.....	8
6.3 Isolation of the cellular RNA.....	9
6.3.1 General.....	9
6.3.2 Using blood collection tubes with RNA profile stabilizers.....	9
6.3.3 Using blood collection tubes without RNA profile stabilizers.....	10
6.4 Quantity and quality assessment of isolated cellular RNA.....	10
6.5 Storage of isolated cellular RNA.....	11
6.5.1 General.....	11
6.5.2 Cellular RNA isolated with commercially available kits.....	11
6.5.3 Cellular RNA isolated with the laboratory's own protocols.....	11
<b>Annex A (informative) Impact of pre-examination process steps on venous whole blood cellular RNA profiles</b> .....	<b>12</b>
<b>Annex B (informative) Influence of blood storage temperature on blood cellular RNA profiles</b> .....	<b>16</b>
<b>Bibliography</b> .....	<b>19</b>

## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see [www.iso.org/directives](http://www.iso.org/directives)).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see [www.iso.org/patents](http://www.iso.org/patents)).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see [www.iso.org/iso/foreword.html](http://www.iso.org/iso/foreword.html).

This document was prepared by Technical Committee ISO/TC 212, *Clinical laboratory testing and in vitro diagnostic test systems*.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at [www.iso.org/members.html](http://www.iso.org/members.html).

A list of all parts in the ISO 20186 series can be found on the ISO website.

## Introduction

Molecular in vitro diagnostics has enabled significant progress in medicine. Further progress is expected by new technologies analysing profiles of nucleic acids, proteins, and metabolites in human tissues and body fluids. However, the profiles of these molecules can change drastically during the pre-examination process, including the specimen collection, transport, storage, and processing. Consequently, this makes the outcome from diagnostics or research unreliable or even impossible, because the subsequent examination might not determine the real situation in the patient but an artificial profile generated during the pre-examination process.

Blood cellular RNA profiles can change significantly after blood collection. Therefore, special measures need to be taken to secure good quality blood samples for cellular RNA examination and storage.

Standardization of the entire workflow from specimen collection to the cellular RNA examination is needed. Studies have been undertaken to determine the important influencing factors. This document draws upon such work to codify and standardize the steps for venous whole blood cellular RNA examination in what is referred to as the pre-examination phase.

In this document, the following verbal forms are used:

- “shall” indicates a requirement;
- “should” indicates a recommendation;
- “may” indicates a permission;
- “can” indicates a possibility or a capability.

ITEH Standards  
(<https://standards.iteh.ai>)  
Document Preview

[ISO 20186-1:2019](https://standards.iteh.ai/catalog/standards/iso/5679f06c-d055-401a-b0f6-ed9a5b033a5d/iso-20186-1-2019)

<https://standards.iteh.ai/catalog/standards/iso/5679f06c-d055-401a-b0f6-ed9a5b033a5d/iso-20186-1-2019>



# Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for venous whole blood —

## Part 1: Isolated cellular RNA

### 1 Scope

This document gives guidelines on the handling, storage, processing and documentation of venous whole blood specimens intended for cellular RNA examination during the pre-examination phase before a molecular examination is performed. This document covers specimens collected in venous whole blood collection tubes.

This document is applicable to any molecular in vitro diagnostic examination performed by medical laboratories. It is also intended to be used by laboratory customers, in vitro diagnostics developers and manufacturers, biobanks, institutions and commercial organizations performing biomedical research, and regulatory authorities.

Different dedicated measures are taken for stabilizing blood cell free circulating RNA and RNA in exosomes circulating in blood. These are not described in this document.

Different dedicated measures are taken for collecting, stabilizing, transporting and storing capillary blood as well as for collecting and storing blood by paper based technologies or other technologies generating dried blood. These are not described in this document.

This document does not cover the isolation of specific blood cells and subsequent isolation of cellular RNA therefrom.

RNA in pathogens present in blood is not covered by this document.

### 2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 15189:2012, *Medical laboratories — Requirements for quality and competence*

### 3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <http://www.electropedia.org/>

#### 3.1

##### **ambient temperature**

unregulated temperature of the surrounding air

**3.2**

**analyte**

component represented in the name of a measurable quantity

[SOURCE: ISO 17511:2003, 3.2]

**3.3**

**backflow**

flow of a liquid opposite to the usual or desired direction

**3.4**

**blood cellular RNA**

**cellular RNA**

RNA molecules present in blood cells

**3.5**

**blood cellular RNA profile**

amounts of different RNA molecules, that are present in blood cells and that can be measured in the absence of any losses, inhibition and interference

**3.6**

**blood cellular RNA profile stabilizers**

compounds, solutions or mixtures that are designed to minimize changes of the *blood cellular RNA profile* (3.5)

**3.7**

**blood collection set**

intravenous device specialized for venepuncture consisting of a stainless steel beveled needle and tube (tubing) with attached plastic wings and fitting connector

Note 1 to entry: The connector attaches to an additional blood collection device, such as a *blood collection tube* (3.8).

**3.8**

**blood collection tube**

tube used for blood collection, usually in a vacuum which forces blood from the vein through the needle into the tube

**3.9**

**closed system**

non-modifiable system provided by the vendor including all necessary components for the examination (i.e. hardware, software, procedures and reagents)

**3.10**

**deoxyribonucleic acid**

**DNA**

polymer of deoxyribonucleotides occurring in a double-stranded (dsDNA) or single-stranded (ssDNA) form

[SOURCE: ISO 22174:2005, 3.1.2]

**3.11**

**deoxyribonuclease**

**DNase**

enzyme that catalyzes the degradation of DNA into smaller components



**3.12**  
**examination**  
**analytical test**

set of operations having the object of determining the value or characteristics of a property

[SOURCE: ISO 15189:2012, 3.7, modified — Term and definition are used here without the original notes; an additional term was added.]

Note 1 to entry: Processes that start with the isolated *analyte* (3.2) and include all kinds of parameter testing or chemical manipulation for quantitative or qualitative examination.

**3.13**  
**examination performance**  
**analytical test performance**  
**analytical performance**

ability of an examination procedure to measure or detect a particular *analyte* (3.2)

Note 1 to entry: Analytical performance is determined from analytical performance studies used to assess the ability of an in vitro diagnostic examination procedure to measure or detect a particular analyte.

Note 2 to entry: Analytical performance includes such characteristics as analytical sensitivity, detection limit, analytical specificity (interference and cross-reactivity), trueness, precision and linearity.

[SOURCE: ISO/TS 17822-1:2014, 3.2, modified — Two terms have been added.]

**3.14**  
**examination provider**  
**analytical test provider**

entity that provides the specific analytical test

**3.15**  
**interfering substance**

endogenous or exogenous substances in clinical *specimens* (3.18)/*samples* (3.24) that can alter an *examination* (3.12) result

Note 1 to entry: Examples of endogenous substances are blood components and acidic polysaccharides.

Note 2 to entry: Examples of exogenous substances are talc and anticoagulant.

**3.16**  
**needle holder**

barrel used in routine venepuncture procedures to hold the *blood collection tube* (3.8) in place and to protect the phlebotomist from direct contact with blood

**3.17**  
**pre-examination processes**  
**preanalytical phase**  
**preanalytical workflow**

processes that start, in chronological order, from the clinician's request and include the examination request, preparation and identification of the patient, collection of the *primary sample(s)* (3.18), transportation to and within the medical laboratory, isolation of analytes, and end when the analytical examination begins

Note 1 to entry: The pre-examination phase includes preparative processes, e.g. RNA isolation procedures, which influence the outcome of the intended examination.

[SOURCE: ISO 15189:2012, 3.15, modified — An additional term was added and more detail was included.]

**3.18**  
**primary sample specimen**

discrete portion of a body fluid, breath, hair or tissue taken for examination, study or analysis of one or more quantities or properties assumed to apply for the whole

[SOURCE: ISO 15189:2012, 3.16, modified — Notes to entry have been omitted.]

**3.19**  
**primary sample collection device**

apparatus specifically intended by an IVD manufacturer to obtain, contain and preserve a body fluid or tissue for in vitro diagnostic examination

Note 1 to entry: Includes devices intended to store a specimen prior to examination.

Note 2 to entry: Includes both vacuum and non-vacuum specimen collection devices.

[SOURCE: ISO 18113-1:2009, 3.55]

**3.20**  
**proficiency testing**

evaluation of participant performance against pre-established criteria by means of interlaboratory comparisons

[SOURCE: ISO 17043:2010, 3.7, modified — Notes to entry have been omitted.]

**3.21**  
**ribonucleic acid RNA**

polymer of ribonucleotides occurring in a double-stranded or single-stranded form

[SOURCE: ISO 22174:2005, 3.1.3]

**3.22**  
**ribonuclease RNase**

enzyme that catalyses the degradation of RNA into smaller components

**3.23**  
**room temperature**

temperature in the range of 18 °C to 25 °C

Note 1 to entry: The definition is given for the purposes of this document. Local or national regulations can have different definitions.

**3.24**  
**sample**

one or more parts taken from a *primary sample* (3.18)

[SOURCE: ISO 15189:2012, 3.24, modified — The example has been omitted.]

**3.25**  
**stability**

ability of a sample material, when stored under specified conditions, to maintain a stated property value within specified limits for a specified period of time

[SOURCE: ISO Guide 30:2015, 2.1.15, modified — The phrase “reference material” has been replaced by “sample material”.]